Evidence map›Paper›PMID 27109632›Full record

ArticleMolecular therapy : the journal of the American Society of Gene Therapy2016

Development of Novel Small Hairpin RNAs That do not Require Processing by Dicer or AGO2.

Shin-Ichiro Ohno, Karen Itano, Yuichirou Harada, Koutaro Asada, Keiki Oikawa, Mikie Kashiwazako, Hikaru Okuyama, Katsuyoshi Kumagai, Masakatsu Takanashi, Katsuko Sudo and 2 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Shin-Ichiro OhnoDepartment of Molecular Pathology, Tokyo Medical University, Tokyo, Japan.
Karen ItanoDepartment of Molecular Pathology, Tokyo Medical University, Tokyo, Japan.
Yuichirou HaradaDepartment of Molecular Pathology, Tokyo Medical University, Tokyo, Japan.
Koutaro AsadaDepartment of Molecular Pathology, Tokyo Medical University, Tokyo, Japan.
Keiki OikawaDepartment of Molecular Pathology, Tokyo Medical University, Tokyo, Japan.
Mikie KashiwazakoDepartment of Molecular Pathology, Tokyo Medical University, Tokyo, Japan.
Hikaru OkuyamaDepartment of Molecular Pathology, Tokyo Medical University, Tokyo, Japan.
Katsuyoshi KumagaiDepartment of Animal Research Center, Tokyo Medical University, Tokyo, Japan.
Masakatsu TakanashiDepartment of Molecular Pathology, Tokyo Medical University, Tokyo, Japan.
Katsuko SudoDepartment of Animal Research Center, Tokyo Medical University, Tokyo, Japan.
Norihiko IkedaDepartment of Respiratory Surgery, Tokyo Medical University, Tokyo, Japan.
Masahiko KurodaDepartment of Molecular Pathology, Tokyo Medical University, Tokyo, Japan.
Tokyo Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The innate cytokine response to nucleic acid is the most challenging problem confronting the practical use of nucleic acid medicine. The degree of stimulation of the innate cytokine response strongly depends on the length of the nucleic acid. In this study, we developed a 30-nucleotide single-strand RNA, termed "guide hairpin RNA (ghRNA, ghR)", that has a physiological function similar to that of miRNA and siRNA. The ghR caused no innate cytokine response either in vitro or in vivo. In addition, its structure does not contain a passenger strand seed sequence, reducing the unwanted gene repression relative to existing short RNA reagents. Systemic and local injection of ghR-form miR-34a (ghR-34a) suppressed tumor growth in a mouse model of RAS-induced lung cancer. Furthermore, Dicer and AGO2 are not required for ghR-34a function. This novel RNA interference (RNAi) technology may provide a novel, safe, and effective nucleic acid drug platform that will increase the clinical usefulness of nucleic acid therapy.

Indexed as

AnimalsArgonaute ProteinsBase PairingBase SequenceCell LineCRISPR-Cas SystemsDisease Models, AnimalGene ExpressionGene Knockdown TechniquesHumansLung NeoplasmsMiceNucleic Acid ConformationProtein BindingRibonuclease IIIRNA, Guide, CRISPR-Cas SystemsAGO2 protein, humanArgonaute ProteinsRibonuclease IIIRNA, Guide, CRISPR-Cas SystemsRNA, MessengerRNA, Small Interfering

Identifiers

PMID27109632
PMCPMC5088761
OpenAlexW2342679269

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.